Inventor · disambiguated record
Ge Wei
Also filed as: WEI GE
25 granted patents·15 pending applications·219 citations·filing 2005–2025
96Inventor score
Top patents by PatentIndex Score
40 records- 0198US11066656B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2020·Granted Jul 20, 2021·30 cites·25 claims
- 0298US11041149B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2020·Granted Jun 22, 2021·32 cites·17 claims
- 0398US10865400B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2016·Granted Dec 15, 2020·25 cites·18 claims
- 0497US12104185B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Oct 1, 2024·2 cites·11 claims
- 0597US12091692B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2021·Granted Sep 17, 2024·3 cites·40 claims
- 0697US12077791B2PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereofHALOZYME INC·Filed 2023·Granted Sep 3, 2024·1 cites·10 claims
- 0797US12018298B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Jun 25, 2024·1 cites·22 claims
- 0897US11952600B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Apr 9, 2024·2 cites·21 claims
- 0997US9447401B2PH20 polypeptide variants, formulations and uses thereofWEI GE·Filed 2012·Granted Sep 20, 2016·47 cites·49 claims
- 1094US12264345B1PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Apr 1, 2025·0 cites·17 claims
- 1193US12195773B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Granted Jan 14, 2025·0 cites·15 claims
- 1293US9284543B2Neutral active soluble truncated PH20 polypeptides and uses thereofWEI GE·Filed 2012·Granted Mar 15, 2016·39 cites·22 claims
- 1393US2025051747A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Application pending·0 cites
- 1492US12037618B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2021·Granted Jul 16, 2024·1 cites·40 claims
- 1592US8927249B2Extended soluble PH20 polypeptides and uses thereofWEI GE·Filed 2009·Granted Jan 6, 2015·26 cites·37 claims
- 1692US2025154488A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2024·Application pending·0 cites
- 1790US12371685B2PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereofHALOZYME INC·Filed 2023·Granted Jul 29, 2025·0 cites·10 claims
- 1890US12152262B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2023·Granted Nov 26, 2024·0 cites·13 claims
- 1988US12123035B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 22, 2024·0 cites·34 claims
- 2088US12110520B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 8, 2024·0 cites·35 claims
- 2188US12104184B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 2288US12060590B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Aug 13, 2024·0 cites·35 claims
- 2388US12054758B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Aug 6, 2024·0 cites·40 claims
- 2488US12049652B2PH20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Granted Jul 30, 2024·0 cites·40 claims
- 2588US2023287381A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2022·Application pending·0 cites
- 2682US2025197835A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 2782US2025197832A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 2882US2025197834A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 2982US2025197833A1Ph20 polypeptide variants, formulations and uses thereofHALOZYME INC·Filed 2025·Application pending·0 cites
- 3078US8457902B2Method for selecting SIRNAs from a plurality of SIRNAs for gene silencingJACKSON AIMEE L·Filed 2011·Granted Jun 4, 2013·1 cites·13 claims
- 3177US10869864B2Combinations for the treatment of cancerIGNYTA INC·Filed 2016·Granted Dec 22, 2020·1 cites·15 claims
- 3277US9683985B2Methods for assessing and identifying or evolving conditionally active therapeutic proteinsKODANDAPANI LALITHA·Filed 2011·Granted Jun 20, 2017·8 cites·32 claims
- 3364US2021322439A1Compositions and methods for treating patients with rtk mutant cellsIGNYTA INC·Filed 2021·Application pending·0 cites
- 3460US2021113555A1Combinations for the treatment of cancerIGNYTA INC·Filed 2020·Application pending·0 cites
- 3553US2015196625A9Metal Sensitive Mutants of Matrix Metalloproteases and uses thereofPALADINI RUDOLPH D·Filed 2014·Application pending·0 cites
- 3646US2015071923A1Modified anti-epidermal growth factor receptor antibodies and methods of use thereofWEI GE·Filed 2014·Application pending·0 cites
- 3744US2015010529A1Thermally stable ph20 hyaluronidase variants and uses thereofWEI GE·Filed 2014·Application pending·0 cites
- 3844US2018177792A1Compositions and methods for treating patients with rtk mutant cellsIGNYTA INC·Filed 2016·Application pending·0 cites
- 3942US2014170159A9Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereofWEI GE·Filed 2013·Application pending·0 cites
- 4039US2008206810A1Truncated St6galnaci Polypeptides and Nucleic AcidsNEOSE TECHNOLOGIES INC·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ge Wei files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →